Exposed by Her Own Victory: 65-Year-Old Veteran Combat Medic Disarms Her Toxic Ex-Husband at a $5 Million Hospital Gala, Unlocking a Medical Scandal That Changes Everything
Weeks later, the sterile hum of the deposition room at St. Jude’s Medical Center felt a world away from the chaos of the gala. My attorney, Mr. Harrison, sat beside me, his notepad filled with careful scribbles. Across the long table, Victor’s legal team, led by Ms. Albright, projected an air of confident disdain.
Dr. Aris Kincaid, St. Jude’s lead pharmacologist, shifted uncomfortably in the witness chair. He was a nervous man, his eyes darting between the lawyers and the omnipresent videographer whose lens silently captured every strained breath.
“Dr. Kincaid,” Ms. Albright began, her voice smooth and predatory, “can you confirm that all clinical trials for the Gable Trauma Protocol, specifically those related to the efficacy of the vascular coagulant, were conducted in full compliance with federal regulations and ethical guidelines?”
Kincaid adjusted his glasses. “Yes, Ms. Albright. Absolutely. All publicly available data shows complete compliance.” His voice was thin, a little too high-pitched.
“And there were no anomalies? No discrepancies in patient outcomes?” she pressed, her gaze unwavering.
He hesitated, a bead of sweat tracing a path down his temple. “None that were ultimately significant to the approved protocol, no.” He wrung his hands beneath the table, a nervous habit I noticed.
Mr. Harrison leaned forward. “Dr. Kincaid, focusing on the early-stage trials, specifically those prior to 2018, were there any initial patient groups whose data required further review or… exclusion?”
Kincaid swallowed hard. His eyes flickered to Ms. Albright, who gave an almost imperceptible shake of her head.
“No, Mr. Harrison. All patient data was included in the final analysis, as per standard protocol.” His voice wavered slightly.
“Are you absolutely certain?” I interjected, my voice cutting through the formal drone. “Because my records from the original patent filing indicate some initial data irregularities in early batches. Specifically, I recall concerns about… delayed neurological responses.”
Kincaid’s eyes, already wide, snapped to me. He flinched, as if I’d struck him. A sudden, palpable tension filled the room. Ms. Albright’s jaw tightened.
“Those… those were minor, quickly resolved issues, Dr. Hollister,” Kincaid stammered, his face flushing crimson. He looked desperately at Ms. Albright again.
“Minor issues involving what, precisely?” Mr. Harrison prompted, sensing the shift. “Which specific batch number are we discussing?”
Kincaid’s breath hitched. He closed his eyes for a brief moment, as if praying. When he opened them, a desperate resignation had settled over him.
“It was… it was regarding suppressed trial batch number four-oh-two,” he blurted out, the words rushing out in a terrified torrent. “We determined the cohort was… an outlier, statistically. Not indicative of the overall trend.”
The room went silent, save for the faint whir of the videographer’s camera. Ms. Albright froze, her carefully composed expression shattering into pure fury. Kincaid, realizing what he’d just said, clapped a hand over his mouth, his eyes wide with horror.
“Suppressed?” Mr. Harrison repeated, his voice dangerously quiet. “You mean hidden from the public record?”
Kincaid could only shake his head, a single tear escaping the corner of his eye. The videographer, oblivious to the implications, simply continued to record, capturing the damning slip of the tongue for posterity.
More Stories
+ There are no comments
Add yours